Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, open-label study was designed to investigate the pharmacokinetic, safety, and tolerability profiles of sofosbuvir and its metabolites (GS-556500 and GS-331007) after a single dose of sofosbuvir 400 mg and once daily dosing of sofosbuvir 400 mg for 7 days in healthy Chinese subjects

Trial Profile

Phase I, open-label study was designed to investigate the pharmacokinetic, safety, and tolerability profiles of sofosbuvir and its metabolites (GS-556500 and GS-331007) after a single dose of sofosbuvir 400 mg and once daily dosing of sofosbuvir 400 mg for 7 days in healthy Chinese subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 12 Sep 2018 New trial record
    • 02 Sep 2018 Results published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top